3 British Biotech Stocks Trading Up To 54% Below Fair Value

Higher inflation worries after comments from a senior US Federal Reserve official have pushed investors to reassess where real growth might come from next. Attention often swings to sectors that are less tied to interest rates and more to scientific progress, which is where UK biotechnology stocks come in. This article walks through three screened biotech shares with balance sheets and valuations that may appeal to patient investors.

The three stocks in this article are just a starting sample, and the full screen surfaced 3 more UK biotech companies with equally compelling stories that are not covered below. To identify, compare, and analyze those extra opportunities alongside the ones featured here, head straight into the Biotech Stocks screener.

Hikma Pharmaceuticals (LSE:HIK)

Hikma Pharmaceuticals sits slightly differently to many pure-play biotech stocks, with its appeal anchored in a large injectables franchise and branded oncology and hospital drugs that plug directly into biotech-driven treatment demand.

Hikma Pharmaceuticals develops generic, specialty, and branded medicines across injectables, oral and respiratory formats, with Injectables generating about $1.4b in revenue, Hikma Rx $1.0b, Branded $0.9b, and a £3.6b market value signalling a sizeable listed healthcare group.

"Hikma Pharmaceuticals is materially increasing R&D investment and concentrating it through three global platforms with disciplined NPV and IRR stage gates, which aims to shift the portfolio toward fewer, higher value complex products that can support higher net margins and earnings quality over time."

What really matters now is how one unseen pressure on this complex drugs mix ultimately feeds through to those future margins and cash flows.

That pressure point is exactly what the full narrative for Hikma Pharmaceuticals unpacks, showing how Hikma Pharmaceuticals' shifting product mix could either compress or accelerate future economics.

Oxford Biomedica (LSE:OXB)

Oxford Biomedica gives the Biotech Stocks screener direct exposure to gene and cell therapy manufacturing, using its LentiVector platform and viral vector CDMO services to support partners that rely on outsourced production capacity rather than building it all in house.

Oxford Biomedica focuses on viral vector development and manufacturing for gene and cell therapies, with revenue mainly from manufacturing services of £88 million, development services of £60 million, procurement services of £22 million and licences, milestones and royalties of £5 million, and a market value of about £652 million.

"Although Oxford Biomedica reports a growing commercial pipeline measured in the hundreds of millions of dollars, the recent drop from about $730 million to roughly $660 million as opportunities moved into signed orders could still leave a gap if new prospects do not refill the funnel at the same pace, which would pressure medium term revenue and operating earnings once the current backlog is worked through."

Whether Oxford Biomedica converts that strengthening position into durable margins will hinge on how one timing sensitive pressure in the model resolves.

If that refill risk is what you are watching, the full narrative for Oxford Biomedica describes how Oxford Biomedica could potentially turn a lumpy order book into long term value.

Genus (LSE:GNS)

Genus is a £1.5b animal genetics specialist that fits the biotech theme through its genomic breeding work, with Genus PIC generating about £355.8 million, Genus ABS £299.8 million and a small £2.5 million Central segment rounding out the commercial footprint.

Unlike most biotech stocks focused on human medicine, Genus links the theme to the farm gate, using genetics and reproductive science to reshape how pigs and cattle are bred. That is exactly where the next leg of potential value sits.

"The build out of Genus’ high margin, recurring PIC royalty model, including more than 50% royalty revenue growth in China on top of 6% group royalty growth in H1 FY26, points to further expansion of royalty driven revenue and operating profit as contracts mature and penetrate a larger share of global pig herds."

What investors cannot yet see clearly is how one shift in the mix of that royalty income could ripple through future returns and cash generation.

If that shift is what you care about, the full narrative for Genus shows how Genus’ royalty mix could accelerate cash generation or quietly cap returns.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. By the time momentum is obvious, the cleanest entry points can be gone. Scan these curated shortlists while the data still matters and get in early.

• Spot mature, cash-rich companies before they hit every headline by running through the curated list of solid balance sheet and fundamentals (10 results) that filters for resilience and financial strength.
• Target income streams that can anchor your portfolio by reviewing the curated 5 dividend fortresses focused on higher yielding businesses with robust fundamentals.
• Position ahead of the next infrastructure wave by checking the curated 39 power grid technology and infrastructure stocks pointing to grid and electrification plays aligned with long term spending plans.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com